Bristol-Myers Financial Statements (BMY)
|
|
|
|
Report date
|
|
|
09.02.2022 |
14.02.2023 |
13.02.2024 |
12.02.2025 |
11.02.2026 |
|
30.04.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
46 385 |
46 159 |
45 006 |
48 300 |
48 194 |
|
48 482 |
|
Operating Income, bln rub |
|
|
9 540 |
9 271 |
8 472 |
9 658 |
12 696 |
|
12 446 |
|
EBITDA, bln rub |
? |
|
20 118 |
19 221 |
19 366 |
3 168 |
14 545 |
|
13 776 |
|
Net profit, bln rub |
? |
|
6 994 |
6 327 |
8 025 |
-8 948 |
7 053 |
|
7 275 |
|
|
OCF, bln rub |
? |
|
16 207 |
13 066 |
13 860 |
15 190 |
14 156 |
|
13 306 |
|
CAPEX, bln rub |
? |
|
973.0 |
1 118 |
1 209 |
1 248 |
1 311 |
|
1 398 |
|
FCF, bln rub |
? |
|
15 234 |
11 948 |
12 651 |
13 942 |
12 845 |
|
11 908 |
|
Dividend payout, bln rub
|
|
|
4 396 |
4 634 |
4 744 |
4 863 |
5 045 |
|
5 070 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
62.9% |
73.2% |
59.1% |
0.00% |
71.5% |
|
69.7% |
|
|
OPEX, bln rub |
|
|
17 221 |
17 219 |
16 885 |
17 774 |
19 906 |
|
20 884 |
|
Cost of production, bln rub |
|
|
19 624 |
19 669 |
19 649 |
20 868 |
15 592 |
|
15 152 |
|
R&D, bln rub |
|
|
9 533 |
9 411 |
9 207 |
9 782 |
9 612 |
|
10 025 |
|
Interest expenses, bln rub |
|
|
1 334 |
1 232 |
1 166 |
1 947 |
1 510 |
|
1 016 |
|
|
Assets, bln rub |
|
|
109 314 |
96 820 |
95 159 |
92 603 |
90 038 |
|
86 476 |
|
Net Assets, bln rub |
? |
|
35 946 |
31 061 |
29 430 |
16 335 |
18 473 |
|
20 068 |
|
Debt, bln rub |
|
|
45 596 |
40 717 |
41 464 |
51 200 |
47 139 |
|
44 460 |
|
Cash, bln rub |
|
|
17 221 |
9 253 |
12 280 |
10 859 |
10 673 |
|
10 486 |
|
Net debt, bln rub |
|
|
28 375 |
31 464 |
29 184 |
40 341 |
36 466 |
|
33 974 |
|
|
Ordinary share price, rub |
|
|
62.4 |
72.0 |
51.3 |
56.6 |
53.9 |
|
56.8 |
|
Number of ordinary shares, mln |
|
|
2 221 |
2 130 |
2 069 |
2 027 |
2 041 |
|
2 044 |
|
|
Market cap, bln rub |
|
|
138 479 |
153 254 |
106 160 |
114 647 |
110 092 |
|
116 041 |
|
EV, bln rub |
? |
|
166 854 |
184 718 |
135 344 |
154 988 |
146 558 |
|
150 015 |
|
Book value, bln rub |
|
|
-27 331 |
-26 443 |
-19 224 |
-29 027 |
-22 384 |
|
-19 916 |
|
|
EPS, rub |
? |
|
3.15 |
2.97 |
3.88 |
-4.41 |
3.46 |
|
3.56 |
|
FCF/share, rub |
|
|
6.86 |
5.61 |
6.11 |
6.88 |
6.29 |
|
5.83 |
|
BV/share, rub |
|
|
-12.3 |
-12.4 |
-9.29 |
-14.3 |
-11.0 |
|
-9.75 |
|
|
EBITDA margin, % |
? |
|
43.4% |
41.6% |
43.0% |
6.56% |
30.2% |
|
28.4% |
|
Net margin, % |
? |
|
15.1% |
13.7% |
17.8% |
-18.5% |
14.6% |
|
15.0% |
|
FCF yield, % |
? |
|
11.0% |
7.80% |
11.9% |
12.2% |
11.7% |
|
10.3% |
|
ROE, % |
? |
|
19.5% |
20.4% |
27.3% |
-54.8% |
38.2% |
|
36.3% |
|
ROA, % |
? |
|
6.40% |
6.53% |
8.43% |
-9.66% |
7.83% |
|
8.41% |
|
|
P/E |
? |
|
19.8 |
24.2 |
13.2 |
-12.8 |
15.6 |
|
16.0 |
|
P/FCF |
|
|
9.09 |
12.8 |
8.39 |
8.22 |
8.57 |
|
9.74 |
|
P/S |
? |
|
2.99 |
3.32 |
2.36 |
2.37 |
2.28 |
|
2.39 |
|
P/BV |
? |
|
-5.07 |
-5.80 |
-5.52 |
-3.95 |
-4.92 |
|
-5.83 |
|
EV/EBITDA |
? |
|
8.29 |
9.61 |
6.99 |
48.9 |
10.1 |
|
10.9 |
|
Debt/EBITDA |
|
|
1.41 |
1.64 |
1.51 |
12.7 |
2.51 |
|
2.47 |
|
|
R&D/CAPEX, % |
|
|
979.8% |
841.8% |
761.5% |
783.8% |
733.2% |
|
717.1% |
|
|
CAPEX/Revenue, % |
|
|
2.10% |
2.42% |
2.69% |
2.58% |
2.72% |
|
2.88% |
|
| Bristol-Myers shareholders |
